Effect of pioglitazone in combination with glimepiride therapy on various parameters of insulin resistance including lipoprotein subclass levels in patients with type 2 diabetes

Effect of pioglitazone in combination with glimepiride therapy on various parameters of insulin resistance including lipoprotein subclass levels in patients with type 2 diabetes - Effect of pioglitazone on insulin resistance parameters

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002461

Enrollment

Registered

2009-09-10

Start date

2008-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type II Diabeteis

Interventions

Pioglitazone + glimepiride Metformin + glimepiride

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Newly diagnosed type 2 diabetes mellitus

Exclusion criteria

Exclusion criteria: (i) a serum creatinine concentration &#8805;106 &micro;mol/l; (ii) chronic liver disease or a clinical history and/or signs of cardiovascular, cerebrovascular or peripheral arterial disease; (iii) heavy smoking or drinking; and (iv) use of thiazolidinediones, biguanides and/or insulin in the 3 months preceding the study.

Design outcomes

Primary

Measure	Time frame
1) Indies of glucose control. 2) Various adipokines and inflammatory parameters. 3) Abdominal fat distribution by CT. 4) Lipoprotein subclass according to particle size.	—

Countries

Japan

Contacts

Public ContactKoji Nakano

Yamashiro Public Hospital Internal Medicine

knakano@yamashiro-hp.jp0774-72-0235

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026